Cantor Fitzgerald set a $30.00 price objective on Array Biopharma (NASDAQ:ARRY) in a research report sent to investors on Tuesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Array Biopharma’s FY2019 earnings at ($0.74) EPS and FY2020 earnings at ($0.63) EPS.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.